Karnataka seeks wider price caps beyond cancer medicines on other high-cost life-saving drugs

The NPPA’s proposal would limit trade margins on selected non-scheduled anti-cancer medicines to 30% of their maximum retail price. This matters because some cancer medicines have large gaps between their procurement cost and the price patients pay. The approval is only in principle, not yet a final list of covered medicines.

The Ministry of Health and Family Welfare has been asked to form an expert committee under the Directorate General of Health Services. That committee will recommend which anti-cancer medicines should come under the measure. The report is expected by October 14. Once the list is finalised, the pricing rule can be applied to the specified medicines.

The Centre estimates that several medicines could become 20% to 70% cheaper at the MRP. Karnataka wants the approach expanded beyond cancer medicines to costly drugs used for cardiac and kidney diseases. The State also wants stronger enforcement against excessive charging and profiteering.

A trade margin is the difference between what a medicine costs in the supply chain and the price at which it is sold. It can include the earnings of distributors, stockists, pharmacies, or other sellers. Limiting the margin is intended to prevent unusually large mark-ups from reaching patients. It does not mean every medicine will automatically cost 30% above its landing cost.

The proposal sets the trade margin at 30% of the medicine’s MRP. The maximum permitted price would depend on the applicable pricing base and the way the final price is calculated. This is why the article says the cap can substantially reduce out-of-pocket spending, without giving one identical final price for all medicines.

For example, a medicine costing about ₹3,000 to procure was reportedly sold for ₹27,000. A controlled margin would narrow that gap. The exact reduction would vary by medicine, but the Centre estimates MRP cuts of 20% to 70% for several anti-cancer medicines.

The possible reduction is substantial: the Centre estimates that the MRP of several anti-cancer medicines could fall by 20% to 70%. The measure could save patients around ₹2,500 crore overall. These are estimates, and the final impact will depend on which medicines the expert committee includes and how their prices are calculated.

The scale becomes clearer from the examples cited by Karnataka’s Health Minister. One cancer drug or injection costing around ₹3,250 was reportedly priced at ₹23,347. Another medicine with a landing cost of about ₹3,000 was being sold for ₹27,000. A 30% trade-margin cap would reduce the room for such large mark-ups.

The measure has not yet become a final, universal price rule for every anti-cancer medicine. The NPPA gave in-principle approval on October 8, while an expert committee is expected to recommend the covered medicines by October 14. Broader savings depend on implementation and enforcement.

The article links the gap to substantial mark-ups between a medicine’s landing or procurement cost and the amount charged to patients. Medicines that are not covered by the same price controls as scheduled medicines can have more scope for high trade margins. Hospitals, distributors, and sellers may therefore charge far above the cost at which the medicine entered the supply chain.

Karnataka cited a medicine with a landing cost of about ₹3,000 that was sold for ₹27,000. It also mentioned a cancer drug or injection costing around ₹3,250 but priced at ₹23,347. These examples show how a medicine’s final price can become many times higher than its purchase cost when margins are not effectively controlled.

The proposed rule would limit trade margins for selected non-scheduled anti-cancer medicines to 30% of MRP. The final ceiling would depend on the applicable pricing base. Karnataka also wants stronger oversight and enforcement against excessive charging and profiteering.

For patients, the main benefit would be lower prices for costly cancer medicines and smaller bills at the point of treatment. The Centre estimates that several anti-cancer medicine MRPs could fall by 20% to 70%. Karnataka argues that price rationalisation should translate into direct savings, rather than merely changing prices somewhere else in the supply chain.

The need is illustrated by the reported prices of cancer medicines. A drug or injection costing around ₹3,250 was reportedly priced at ₹23,347. Another medicine with a landing cost of about ₹3,000 was sold for ₹27,000. A 30% trade-margin cap would restrict the mark-up and could substantially lower patients’ out-of-pocket expenditure.

The Minister said cancer treatment often pushes families into debt, forcing them to exhaust savings and sell assets. The proposed measure could save patients around ₹2,500 crore. Its actual reach will depend on the final medicine list, implementation, and enforcement. Karnataka wants similar action for other life-saving treatments.

Karnataka is asking for wider controls because the problem is not limited to cancer treatment. The State says high-cost, life-saving medicines used for cardiac and kidney diseases can also place a heavy financial burden on patients. Its goal is for price rationalisation to reach people facing other expensive medical treatments.

The State’s inspections found substantial differences between medicine procurement costs and the prices charged to patients. Karnataka identified pricing concerns involving 253 medicines and consumables with mark-ups. It has asked the Centre to expand price-control oversight and impose a comprehensive cap on trade margins for high-cost and life-saving medicines.

The proposed anti-cancer measure would be a starting point, not the full policy sought by Karnataka. The State also wants advanced chemotherapy, targeted therapy, and other expensive cancer medicines included under the Drugs (Prices Control) Order. It has requested stronger enforcement against excessive charging and greater disclosure of medicine costs in hospital bills.

India’s system distinguishes between scheduled and non-scheduled medicines under the Drugs (Prices Control) Order, 2013. The article states that scheduled medicines have a trade-margin limit of 16% above the price to retailers. It also describes the NPPA’s proposed 30% cap for selected non-scheduled anti-cancer medicines, whose prices have raised concerns.

The NPPA is the national authority involved in pharmaceutical price regulation. It approved the anti-cancer proposal in principle and is awaiting an expert committee’s list of medicines. The DPCO supplies the legal framework for price control, including Paragraph 19, under which the identified non-scheduled anti-cancer medicines are being considered.

The article does not describe every operating rule for both categories. It does show the policy gap Karnataka wants addressed. The State has asked for wider oversight, stronger enforcement, and inclusion of expensive cardiac, kidney, chemotherapy, and targeted-therapy medicines. It also cited the Supreme Court’s question about extending a 16% ceiling.